[Treatment of hepatic veno-occlusive disease after bone marrow transplantation with recombinant human tissue plasminogen activator (rh-tPA)].

Abstract

Ten children were treated with recombinant human tissue plasminogen activator (rh-tPA) for severe hepatic veno-occlusive disease (VOD) that developed after bone marrow transplantation. Treatment with rh-tPA was begun a median of 22 days (range; 13-127 days) after transplantation. Seven of 9 (78%) evaluable patients had complete resolution of their VOD. Four patients had hemorrhagic complications, and 2 of them died because of pulmonary hemorrhage and subdural hemorrhage, respectively. Although rh-tPA seems to be an effective therapy for established VOD, further studies will be necessary to determine its safety as well as the optimal dosing regimen.

• Authors: A Yoshimi, K Kato, N Maeda, T Matsuyama, S Kojima
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 41 Issue 2 Pg. 103-8 (Feb 2000) ISSN: 0485-1439 [Print] Japan
• PMID: 10723238 (Publication Type: English Abstract, Journal Article)

Chemical References

• Recombinant Proteins
• Tissue Plasminogen Activator

Topics

• Adolescent
• Bone Marrow Transplantation (adverse effects)
• Child
• Child, Preschool
• Female
• Hematoma, Subdural (chemically induced)
• Hemorrhage (chemically induced)
• Hepatic Veno-Occlusive Disease (drug therapy, etiology)
• Humans
• Infant
• Lung Diseases (diagnosis)
• Male
• Recombinant Proteins (adverse effects, therapeutic use)
• Tissue Plasminogen Activator (adverse effects, therapeutic use)
• Treatment Outcome